XBiotech Inc. XBIT

Company Overview

XBiotech Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing antibody-based therapeutics derived from naturally occurring human immune responses. The company operates within the biopharmaceutical and immunotherapy industries, with a primary emphasis on inflammatory diseases, infectious diseases, cardiovascular conditions, and oncology. Its core technology platform is centered on “True Human” monoclonal antibodies, which are generated from naturally occurring human immune cells rather than engineered or humanized antibody systems.

The company’s primary business activity is the research and clinical development of proprietary therapeutic candidates, with revenue historically derived primarily from collaboration activity, licensing arrangements, and investment income rather than commercialized products. XBiotech was founded in 2005 by Dr. John Simard, who also developed the company’s antibody discovery platform. The company became publicly traded on Nasdaq under the ticker XBIT and has evolved from an early-stage antibody discovery company into a clinical-stage developer pursuing multiple therapeutic programs across immunology and infectious disease indications.